Eli Lilly’s Cyramza fails to improve survival in gastric cancer trial despite meeting initial goal
Lilly gastric cancer drug Cyramza (ramucirumab) did meet the primary endpoint of a phase 3 trial RAINFALL but could not improve overall survival of patients.
In a recent announcement, Eli Lilly and Company disclosed that its phase 3 RAINFALL trial of the drug Cyramza (ramucirumab) for the treatment of HER2-negative metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma achieved mixed results. While the trial met its primary endpoint of progression-free survival (PFS), it did not improve overall survival (OS), a key […]